Re: forced drugging / Lyrica (Pregabalin) -

[Guest guest]

Lyrica = (Pregabalin) which is this years

version of gabapentin (Neurontin) .... all made by my dear old

friends PFIZER

http://www.drugdevelopment-technology.com/projects/pregabalin/

LYRICA (PREGABALIN) - NEW GABAPENTINOID WITH WIDE CLINICAL

APPLICATION

Developed by Pfizer, pregabalin, marketed under the brand name

Lyrica, is a 3-substituted analogue of gamma-amino butyric acid

(GABA) and a compound related to Pfizer's hugely successful

antiepileptic drug gabapentin (Neurontin).

In July 2004, Pfizer secured Europe-wide approval for Lyrica

(pregabalin) for use in the management of peripheral neuropathic

pain as well as an adjunctive therapy in the treatment of partial

epileptic seizures. Subsequently in December 2004 the company gained

FDA approval for use of Lyrica (pregabalin) in neuropathic pain

associated with diabetic peripheral neuropathy and postherpetic

neuralgia; making it the first FDA-approved treatment for both of

these neuropathic pain states. Lyrica (pregabalin) is also being

reviewed by the FDA as an adjunctive treatment for partial epileptic

seizures in adults.

A SUCCESSOR TO GABAPENTIN

First marketed in 1983, gabapentin (Neurontin) has been one of

Pfizer's top performing drugs. Lyrica (pregabalin) is seen as an

important successor now that gabapentin is facing the threat of

generic competition.

Both drugs share a similar mechanism of action: binding to calcium

channels and modulating calcium influx as well as influencing

GABergic neurotransmission. This mode of action translates into anti-

epileptic, analgesic and anxiolytic effects. Because it is more

potent than gabapentin, Lyrica (pregabalin) achieves efficacy at

lower doses. This increases its therapeutic index with respect to

gabapentin and should lead to fewer dose-related side effects.

Clinical studies with Lyrica (pregabalin) have been carried out on

over 10,000 patients worldwide.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN EPILEPSY

Gabapentin is approved worldwide for adjunctive treatment of

patients with partial epilepsy. Because it is not metabolised (and

so does not alter the pharmacokinetics of co-administrated drugs) it

is a good candidate for use in combination with other antiepileptic

medications. Clinical studies with oral Lyrica (pregabalin) suggest

it is at least as effective as gabapentin as adjunctive therapy in

patients refractory to one or more conventional antiepileptic drugs.

In large-scale, placebo-controlled studies of 12 weeks' duration,

add-on therapy with oral Lyrica (pregabalin) reduced seizure

frequency by up to 75%. In these studies doses of Lyrica

(pregabalin) ranged from 150mg to 600mg daily.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND

ANXIETY DISORDER

Neuropathic pain is chronic pain that arises from damage to sensory

nerves. It can include:

Pain arising from trapped or compressed nerves

Drug-induced nerve damage

Diabetic neuropathy

Post-herpetic pain

Phantom limb syndrome following limb amputation

Peripheral neuropathy

Fibromyalgia

Neuropathic pain generally does not respond to treatment with opioid

or non-steroidal anti-inflammatory drugs (NSAIDs). At high doses

gabapentin has proven effective against neuropathic pain induced by

diabetic neuropathy and postherpetic neuralgia. Data from clinical

studies show that Lyrica (pregabalin) shares this analgesic

effectiveness. Efficacy has been demonstrated in a number of

clinical studies, including those in patients with diabetic

neuropathy and fibromyalgia. Treatment of neuropathic pain is seen

as the drug's leading indication.

A double-blind, placebo-controlled monotherapy study in 529 patients

with fibromyalgia, for example, showed that eight weeks' treatment

with Lyrica (pregabalin) 150mg to 450mg per day produced

significantly greater reductions in pain compared with placebo as

well as improving sleep quality and fatigue. Pain, sleep

disturbances and fatigue are core symptoms of fibromyalgia, which

has proved an extremely difficult condition to treat.

Data from a series of phase II and III placebo-controlled clinical

studies in over 1,200 patients with generalised anxiety disorder

suggest that Lyrica (pregabalin) will be effective for this

disabling disorder. In comparison with venlafaxine, pregabalin

provided more rapid relief of psychic and somatic symptoms. In

comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin)

appeared equally effective in reducing somatic symptoms. Overall,

these findings show that Lyrica (pregabalin) combines the benefits

of both antidepressants and benzodiazepines. It appears at least as

rapid as benzodiazepines against somatic symptoms, while providing

more rapid control of psychic symptoms than antidepressants.

MARKETING COMMENTARY

Once generic manufacture of gabapentin is approved, sales of

Pfizer's Neurontin are likely to fall dramatically. Encouraging

physicians to switch patients from Neurontin to Lyrica (pregabalin),

if approved, will be an important strategy in minimising the impact

of generic competition. Lyrica (pregabalin) is as effective as

Neurontin, but at lower doses, which translates to fewer side

effects. Thus, it is well placed to capture Neurontin's market

share. Through the successful launch of follow-on products, Pfizer

has maintained leadership in other CNS areas, such as the market for

antidepressants.

Click here for printable version

SPECIFICATIONS

>

>

> In a message dated 10/14/2006 2:24:06 AM Pacific Standard Time,

> SSRI medications writes:

>

> I am forced to take Lyrica, so that they can get RSD under

control. I now

> have more severe and acute back and abdominal pains, spasms

through out all my

> muscles, having a hard time concentrating, and forgetting little

things from

> minute to minute. Since it's a new drug, it will be years before

the damages

> are exposed

>

>

> How are you FORCED to take this? Are they using it in

suppository form?

> You can always not take it and tell them that you did? What is

Lyrica anyway?

> With the side effects you are experiencing, sounds like you need

to get off

> this poison.

>

>

>

[Guest guest]

Lyrica = (Pregabalin) which is this years

version of gabapentin (Neurontin) .... all made by my dear old

friends PFIZER

http://www.drugdevelopment-technology.com/projects/pregabalin/

LYRICA (PREGABALIN) - NEW GABAPENTINOID WITH WIDE CLINICAL

APPLICATION

Developed by Pfizer, pregabalin, marketed under the brand name

Lyrica, is a 3-substituted analogue of gamma-amino butyric acid

(GABA) and a compound related to Pfizer's hugely successful

antiepileptic drug gabapentin (Neurontin).

In July 2004, Pfizer secured Europe-wide approval for Lyrica

(pregabalin) for use in the management of peripheral neuropathic

pain as well as an adjunctive therapy in the treatment of partial

epileptic seizures. Subsequently in December 2004 the company gained

FDA approval for use of Lyrica (pregabalin) in neuropathic pain

associated with diabetic peripheral neuropathy and postherpetic

neuralgia; making it the first FDA-approved treatment for both of

these neuropathic pain states. Lyrica (pregabalin) is also being

reviewed by the FDA as an adjunctive treatment for partial epileptic

seizures in adults.

A SUCCESSOR TO GABAPENTIN

First marketed in 1983, gabapentin (Neurontin) has been one of

Pfizer's top performing drugs. Lyrica (pregabalin) is seen as an

important successor now that gabapentin is facing the threat of

generic competition.

Both drugs share a similar mechanism of action: binding to calcium

channels and modulating calcium influx as well as influencing

GABergic neurotransmission. This mode of action translates into anti-

epileptic, analgesic and anxiolytic effects. Because it is more

potent than gabapentin, Lyrica (pregabalin) achieves efficacy at

lower doses. This increases its therapeutic index with respect to

gabapentin and should lead to fewer dose-related side effects.

Clinical studies with Lyrica (pregabalin) have been carried out on

over 10,000 patients worldwide.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN EPILEPSY

Gabapentin is approved worldwide for adjunctive treatment of

patients with partial epilepsy. Because it is not metabolised (and

so does not alter the pharmacokinetics of co-administrated drugs) it

is a good candidate for use in combination with other antiepileptic

medications. Clinical studies with oral Lyrica (pregabalin) suggest

it is at least as effective as gabapentin as adjunctive therapy in

patients refractory to one or more conventional antiepileptic drugs.

In large-scale, placebo-controlled studies of 12 weeks' duration,

add-on therapy with oral Lyrica (pregabalin) reduced seizure

frequency by up to 75%. In these studies doses of Lyrica

(pregabalin) ranged from 150mg to 600mg daily.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND

ANXIETY DISORDER

Neuropathic pain is chronic pain that arises from damage to sensory

nerves. It can include:

Pain arising from trapped or compressed nerves

Drug-induced nerve damage

Diabetic neuropathy

Post-herpetic pain

Phantom limb syndrome following limb amputation

Peripheral neuropathy

Fibromyalgia

Neuropathic pain generally does not respond to treatment with opioid

or non-steroidal anti-inflammatory drugs (NSAIDs). At high doses

gabapentin has proven effective against neuropathic pain induced by

diabetic neuropathy and postherpetic neuralgia. Data from clinical

studies show that Lyrica (pregabalin) shares this analgesic

effectiveness. Efficacy has been demonstrated in a number of

clinical studies, including those in patients with diabetic

neuropathy and fibromyalgia. Treatment of neuropathic pain is seen

as the drug's leading indication.

A double-blind, placebo-controlled monotherapy study in 529 patients

with fibromyalgia, for example, showed that eight weeks' treatment

with Lyrica (pregabalin) 150mg to 450mg per day produced

significantly greater reductions in pain compared with placebo as

well as improving sleep quality and fatigue. Pain, sleep

disturbances and fatigue are core symptoms of fibromyalgia, which

has proved an extremely difficult condition to treat.

Data from a series of phase II and III placebo-controlled clinical

studies in over 1,200 patients with generalised anxiety disorder

suggest that Lyrica (pregabalin) will be effective for this

disabling disorder. In comparison with venlafaxine, pregabalin

provided more rapid relief of psychic and somatic symptoms. In

comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin)

appeared equally effective in reducing somatic symptoms. Overall,

these findings show that Lyrica (pregabalin) combines the benefits

of both antidepressants and benzodiazepines. It appears at least as

rapid as benzodiazepines against somatic symptoms, while providing

more rapid control of psychic symptoms than antidepressants.

MARKETING COMMENTARY

Once generic manufacture of gabapentin is approved, sales of

Pfizer's Neurontin are likely to fall dramatically. Encouraging

physicians to switch patients from Neurontin to Lyrica (pregabalin),

if approved, will be an important strategy in minimising the impact

of generic competition. Lyrica (pregabalin) is as effective as

Neurontin, but at lower doses, which translates to fewer side

effects. Thus, it is well placed to capture Neurontin's market

share. Through the successful launch of follow-on products, Pfizer

has maintained leadership in other CNS areas, such as the market for

antidepressants.

Click here for printable version

SPECIFICATIONS

>

>

> In a message dated 10/14/2006 2:24:06 AM Pacific Standard Time,

> SSRI medications writes:

>

> I am forced to take Lyrica, so that they can get RSD under

control. I now

> have more severe and acute back and abdominal pains, spasms

through out all my

> muscles, having a hard time concentrating, and forgetting little

things from

> minute to minute. Since it's a new drug, it will be years before

the damages

> are exposed

>

>

> How are you FORCED to take this? Are they using it in

suppository form?

> You can always not take it and tell them that you did? What is

Lyrica anyway?

> With the side effects you are experiencing, sounds like you need

to get off

> this poison.

>

>

>

[Guest guest]

Lyrica = (Pregabalin) which is this years

version of gabapentin (Neurontin) .... all made by my dear old

friends PFIZER

http://www.drugdevelopment-technology.com/projects/pregabalin/

LYRICA (PREGABALIN) - NEW GABAPENTINOID WITH WIDE CLINICAL

APPLICATION

Developed by Pfizer, pregabalin, marketed under the brand name

Lyrica, is a 3-substituted analogue of gamma-amino butyric acid

(GABA) and a compound related to Pfizer's hugely successful

antiepileptic drug gabapentin (Neurontin).

In July 2004, Pfizer secured Europe-wide approval for Lyrica

(pregabalin) for use in the management of peripheral neuropathic

pain as well as an adjunctive therapy in the treatment of partial

epileptic seizures. Subsequently in December 2004 the company gained

FDA approval for use of Lyrica (pregabalin) in neuropathic pain

associated with diabetic peripheral neuropathy and postherpetic

neuralgia; making it the first FDA-approved treatment for both of

these neuropathic pain states. Lyrica (pregabalin) is also being

reviewed by the FDA as an adjunctive treatment for partial epileptic

seizures in adults.

A SUCCESSOR TO GABAPENTIN

First marketed in 1983, gabapentin (Neurontin) has been one of

Pfizer's top performing drugs. Lyrica (pregabalin) is seen as an

important successor now that gabapentin is facing the threat of

generic competition.

Both drugs share a similar mechanism of action: binding to calcium

channels and modulating calcium influx as well as influencing

GABergic neurotransmission. This mode of action translates into anti-

epileptic, analgesic and anxiolytic effects. Because it is more

potent than gabapentin, Lyrica (pregabalin) achieves efficacy at

lower doses. This increases its therapeutic index with respect to

gabapentin and should lead to fewer dose-related side effects.

Clinical studies with Lyrica (pregabalin) have been carried out on

over 10,000 patients worldwide.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN EPILEPSY

Gabapentin is approved worldwide for adjunctive treatment of

patients with partial epilepsy. Because it is not metabolised (and

so does not alter the pharmacokinetics of co-administrated drugs) it

is a good candidate for use in combination with other antiepileptic

medications. Clinical studies with oral Lyrica (pregabalin) suggest

it is at least as effective as gabapentin as adjunctive therapy in

patients refractory to one or more conventional antiepileptic drugs.

In large-scale, placebo-controlled studies of 12 weeks' duration,

add-on therapy with oral Lyrica (pregabalin) reduced seizure

frequency by up to 75%. In these studies doses of Lyrica

(pregabalin) ranged from 150mg to 600mg daily.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND

ANXIETY DISORDER

Neuropathic pain is chronic pain that arises from damage to sensory

nerves. It can include:

Pain arising from trapped or compressed nerves

Drug-induced nerve damage

Diabetic neuropathy

Post-herpetic pain

Phantom limb syndrome following limb amputation

Peripheral neuropathy

Fibromyalgia

Neuropathic pain generally does not respond to treatment with opioid

or non-steroidal anti-inflammatory drugs (NSAIDs). At high doses

gabapentin has proven effective against neuropathic pain induced by

diabetic neuropathy and postherpetic neuralgia. Data from clinical

studies show that Lyrica (pregabalin) shares this analgesic

effectiveness. Efficacy has been demonstrated in a number of

clinical studies, including those in patients with diabetic

neuropathy and fibromyalgia. Treatment of neuropathic pain is seen

as the drug's leading indication.

A double-blind, placebo-controlled monotherapy study in 529 patients

with fibromyalgia, for example, showed that eight weeks' treatment

with Lyrica (pregabalin) 150mg to 450mg per day produced

significantly greater reductions in pain compared with placebo as

well as improving sleep quality and fatigue. Pain, sleep

disturbances and fatigue are core symptoms of fibromyalgia, which

has proved an extremely difficult condition to treat.

Data from a series of phase II and III placebo-controlled clinical

studies in over 1,200 patients with generalised anxiety disorder

suggest that Lyrica (pregabalin) will be effective for this

disabling disorder. In comparison with venlafaxine, pregabalin

provided more rapid relief of psychic and somatic symptoms. In

comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin)

appeared equally effective in reducing somatic symptoms. Overall,

these findings show that Lyrica (pregabalin) combines the benefits

of both antidepressants and benzodiazepines. It appears at least as

rapid as benzodiazepines against somatic symptoms, while providing

more rapid control of psychic symptoms than antidepressants.

MARKETING COMMENTARY

Once generic manufacture of gabapentin is approved, sales of

Pfizer's Neurontin are likely to fall dramatically. Encouraging

physicians to switch patients from Neurontin to Lyrica (pregabalin),

if approved, will be an important strategy in minimising the impact

of generic competition. Lyrica (pregabalin) is as effective as

Neurontin, but at lower doses, which translates to fewer side

effects. Thus, it is well placed to capture Neurontin's market

share. Through the successful launch of follow-on products, Pfizer

has maintained leadership in other CNS areas, such as the market for

antidepressants.

Click here for printable version

SPECIFICATIONS

>

>

> In a message dated 10/14/2006 2:24:06 AM Pacific Standard Time,

> SSRI medications writes:

>

> I am forced to take Lyrica, so that they can get RSD under

control. I now

> have more severe and acute back and abdominal pains, spasms

through out all my

> muscles, having a hard time concentrating, and forgetting little

things from

> minute to minute. Since it's a new drug, it will be years before

the damages

> are exposed

>

>

> How are you FORCED to take this? Are they using it in

suppository form?

> You can always not take it and tell them that you did? What is

Lyrica anyway?

> With the side effects you are experiencing, sounds like you need

to get off

> this poison.

>

>

>

[Guest guest]

Lyrica = (Pregabalin) which is this years

version of gabapentin (Neurontin) .... all made by my dear old

friends PFIZER

http://www.drugdevelopment-technology.com/projects/pregabalin/

LYRICA (PREGABALIN) - NEW GABAPENTINOID WITH WIDE CLINICAL

APPLICATION

Developed by Pfizer, pregabalin, marketed under the brand name

Lyrica, is a 3-substituted analogue of gamma-amino butyric acid

(GABA) and a compound related to Pfizer's hugely successful

antiepileptic drug gabapentin (Neurontin).

In July 2004, Pfizer secured Europe-wide approval for Lyrica

(pregabalin) for use in the management of peripheral neuropathic

pain as well as an adjunctive therapy in the treatment of partial

epileptic seizures. Subsequently in December 2004 the company gained

FDA approval for use of Lyrica (pregabalin) in neuropathic pain

associated with diabetic peripheral neuropathy and postherpetic

neuralgia; making it the first FDA-approved treatment for both of

these neuropathic pain states. Lyrica (pregabalin) is also being

reviewed by the FDA as an adjunctive treatment for partial epileptic

seizures in adults.

A SUCCESSOR TO GABAPENTIN

First marketed in 1983, gabapentin (Neurontin) has been one of

Pfizer's top performing drugs. Lyrica (pregabalin) is seen as an

important successor now that gabapentin is facing the threat of

generic competition.

Both drugs share a similar mechanism of action: binding to calcium

channels and modulating calcium influx as well as influencing

GABergic neurotransmission. This mode of action translates into anti-

epileptic, analgesic and anxiolytic effects. Because it is more

potent than gabapentin, Lyrica (pregabalin) achieves efficacy at

lower doses. This increases its therapeutic index with respect to

gabapentin and should lead to fewer dose-related side effects.

Clinical studies with Lyrica (pregabalin) have been carried out on

over 10,000 patients worldwide.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN EPILEPSY

Gabapentin is approved worldwide for adjunctive treatment of

patients with partial epilepsy. Because it is not metabolised (and

so does not alter the pharmacokinetics of co-administrated drugs) it

is a good candidate for use in combination with other antiepileptic

medications. Clinical studies with oral Lyrica (pregabalin) suggest

it is at least as effective as gabapentin as adjunctive therapy in

patients refractory to one or more conventional antiepileptic drugs.

In large-scale, placebo-controlled studies of 12 weeks' duration,

add-on therapy with oral Lyrica (pregabalin) reduced seizure

frequency by up to 75%. In these studies doses of Lyrica

(pregabalin) ranged from 150mg to 600mg daily.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND

ANXIETY DISORDER

Neuropathic pain is chronic pain that arises from damage to sensory

nerves. It can include:

Pain arising from trapped or compressed nerves

Drug-induced nerve damage

Diabetic neuropathy

Post-herpetic pain

Phantom limb syndrome following limb amputation

Peripheral neuropathy

Fibromyalgia

Neuropathic pain generally does not respond to treatment with opioid

or non-steroidal anti-inflammatory drugs (NSAIDs). At high doses

gabapentin has proven effective against neuropathic pain induced by

diabetic neuropathy and postherpetic neuralgia. Data from clinical

studies show that Lyrica (pregabalin) shares this analgesic

effectiveness. Efficacy has been demonstrated in a number of

clinical studies, including those in patients with diabetic

neuropathy and fibromyalgia. Treatment of neuropathic pain is seen

as the drug's leading indication.

A double-blind, placebo-controlled monotherapy study in 529 patients

with fibromyalgia, for example, showed that eight weeks' treatment

with Lyrica (pregabalin) 150mg to 450mg per day produced

significantly greater reductions in pain compared with placebo as

well as improving sleep quality and fatigue. Pain, sleep

disturbances and fatigue are core symptoms of fibromyalgia, which

has proved an extremely difficult condition to treat.

Data from a series of phase II and III placebo-controlled clinical

studies in over 1,200 patients with generalised anxiety disorder

suggest that Lyrica (pregabalin) will be effective for this

disabling disorder. In comparison with venlafaxine, pregabalin

provided more rapid relief of psychic and somatic symptoms. In

comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin)

appeared equally effective in reducing somatic symptoms. Overall,

these findings show that Lyrica (pregabalin) combines the benefits

of both antidepressants and benzodiazepines. It appears at least as

rapid as benzodiazepines against somatic symptoms, while providing

more rapid control of psychic symptoms than antidepressants.

MARKETING COMMENTARY

Once generic manufacture of gabapentin is approved, sales of

Pfizer's Neurontin are likely to fall dramatically. Encouraging

physicians to switch patients from Neurontin to Lyrica (pregabalin),

if approved, will be an important strategy in minimising the impact

of generic competition. Lyrica (pregabalin) is as effective as

Neurontin, but at lower doses, which translates to fewer side

effects. Thus, it is well placed to capture Neurontin's market

share. Through the successful launch of follow-on products, Pfizer

has maintained leadership in other CNS areas, such as the market for

antidepressants.

Click here for printable version

SPECIFICATIONS

>

>

> In a message dated 10/14/2006 2:24:06 AM Pacific Standard Time,

> SSRI medications writes:

>

> I am forced to take Lyrica, so that they can get RSD under

control. I now

> have more severe and acute back and abdominal pains, spasms

through out all my

> muscles, having a hard time concentrating, and forgetting little

things from

> minute to minute. Since it's a new drug, it will be years before

the damages

> are exposed

>

>

> How are you FORCED to take this? Are they using it in

suppository form?

> You can always not take it and tell them that you did? What is

Lyrica anyway?

> With the side effects you are experiencing, sounds like you need

to get off

> this poison.

>

>

>

[Guest guest]

When you go to pain management, you have to agree to allow them to test your

blood for compliance to treatment.

Yes, the drug makes you sleep, only after making your feel like your are an

out of control drunk. I suspect that base on my age (58 and a half) that my body

doesn't metabolize very well. I also suspect that the back and abdominal pain

are from affects on kidneys and liver.

When swelling is a side effect, you may bet that there something toxic going

on. Lyrica is a narcotic. If I don't comply with treatment, the surgery to fix

my wrist and arm, will not happen; and, the good old worker's comp will say you

are as good as your going to get, because you don't comply with treatment. I

battled taking anything for as long as I could. I don't trust any drug approved

by the FDA.

Re: forced drugging / Lyrica (Pregabalin) -

Lyrica = (Pregabalin) which is this years

version of gabapentin (Neurontin) .... all made by my dear old

friends PFIZER

http://www.drugdevelopment-technology.com/projects/pregabalin/<http://www.drugde\

velopment-technology.com/projects/pregabalin/>

LYRICA (PREGABALIN) - NEW GABAPENTINOID WITH WIDE CLINICAL

APPLICATION

Developed by Pfizer, pregabalin, marketed under the brand name

Lyrica, is a 3-substituted analogue of gamma-amino butyric acid

(GABA) and a compound related to Pfizer's hugely successful

antiepileptic drug gabapentin (Neurontin).

In July 2004, Pfizer secured Europe-wide approval for Lyrica

(pregabalin) for use in the management of peripheral neuropathic

pain as well as an adjunctive therapy in the treatment of partial

epileptic seizures. Subsequently in December 2004 the company gained

FDA approval for use of Lyrica (pregabalin) in neuropathic pain

associated with diabetic peripheral neuropathy and postherpetic

neuralgia; making it the first FDA-approved treatment for both of

these neuropathic pain states. Lyrica (pregabalin) is also being

reviewed by the FDA as an adjunctive treatment for partial epileptic

seizures in adults.

A SUCCESSOR TO GABAPENTIN

First marketed in 1983, gabapentin (Neurontin) has been one of

Pfizer's top performing drugs. Lyrica (pregabalin) is seen as an

important successor now that gabapentin is facing the threat of

generic competition.

Both drugs share a similar mechanism of action: binding to calcium

channels and modulating calcium influx as well as influencing

GABergic neurotransmission. This mode of action translates into anti-

epileptic, analgesic and anxiolytic effects. Because it is more

potent than gabapentin, Lyrica (pregabalin) achieves efficacy at

lower doses. This increases its therapeutic index with respect to

gabapentin and should lead to fewer dose-related side effects.

Clinical studies with Lyrica (pregabalin) have been carried out on

over 10,000 patients worldwide.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN EPILEPSY

Gabapentin is approved worldwide for adjunctive treatment of

patients with partial epilepsy. Because it is not metabolised (and

so does not alter the pharmacokinetics of co-administrated drugs) it

is a good candidate for use in combination with other antiepileptic

medications. Clinical studies with oral Lyrica (pregabalin) suggest

it is at least as effective as gabapentin as adjunctive therapy in

patients refractory to one or more conventional antiepileptic drugs.

In large-scale, placebo-controlled studies of 12 weeks' duration,

add-on therapy with oral Lyrica (pregabalin) reduced seizure

frequency by up to 75%. In these studies doses of Lyrica

(pregabalin) ranged from 150mg to 600mg daily.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND

ANXIETY DISORDER

Neuropathic pain is chronic pain that arises from damage to sensory

nerves. It can include:

Pain arising from trapped or compressed nerves

Drug-induced nerve damage

Diabetic neuropathy

Post-herpetic pain

Phantom limb syndrome following limb amputation

Peripheral neuropathy

Fibromyalgia

Neuropathic pain generally does not respond to treatment with opioid

or non-steroidal anti-inflammatory drugs (NSAIDs). At high doses

gabapentin has proven effective against neuropathic pain induced by

diabetic neuropathy and postherpetic neuralgia. Data from clinical

studies show that Lyrica (pregabalin) shares this analgesic

effectiveness. Efficacy has been demonstrated in a number of

clinical studies, including those in patients with diabetic

neuropathy and fibromyalgia. Treatment of neuropathic pain is seen

as the drug's leading indication.

A double-blind, placebo-controlled monotherapy study in 529 patients

with fibromyalgia, for example, showed that eight weeks' treatment

with Lyrica (pregabalin) 150mg to 450mg per day produced

significantly greater reductions in pain compared with placebo as

well as improving sleep quality and fatigue. Pain, sleep

disturbances and fatigue are core symptoms of fibromyalgia, which

has proved an extremely difficult condition to treat.

Data from a series of phase II and III placebo-controlled clinical

studies in over 1,200 patients with generalised anxiety disorder

suggest that Lyrica (pregabalin) will be effective for this

disabling disorder. In comparison with venlafaxine, pregabalin

provided more rapid relief of psychic and somatic symptoms. In

comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin)

appeared equally effective in reducing somatic symptoms. Overall,

these findings show that Lyrica (pregabalin) combines the benefits

of both antidepressants and benzodiazepines. It appears at least as

rapid as benzodiazepines against somatic symptoms, while providing

more rapid control of psychic symptoms than antidepressants.

MARKETING COMMENTARY

Once generic manufacture of gabapentin is approved, sales of

Pfizer's Neurontin are likely to fall dramatically. Encouraging

physicians to switch patients from Neurontin to Lyrica (pregabalin),

if approved, will be an important strategy in minimising the impact

of generic competition. Lyrica (pregabalin) is as effective as

Neurontin, but at lower doses, which translates to fewer side

effects. Thus, it is well placed to capture Neurontin's market

share. Through the successful launch of follow-on products, Pfizer

has maintained leadership in other CNS areas, such as the market for

antidepressants.

Click here for printable version

SPECIFICATIONS

>

>

> In a message dated 10/14/2006 2:24:06 AM Pacific Standard Time,

> SSRI medications <mailto:SSRI medications >

writes:

>

> I am forced to take Lyrica, so that they can get RSD under

control. I now

> have more severe and acute back and abdominal pains, spasms

through out all my

> muscles, having a hard time concentrating, and forgetting little

things from

> minute to minute. Since it's a new drug, it will be years before

the damages

> are exposed

>

>

> How are you FORCED to take this? Are they using it in

suppository form?

> You can always not take it and tell them that you did? What is

Lyrica anyway?

> With the side effects you are experiencing, sounds like you need

to get off

> this poison.

>

>

>

[Guest guest]

When you go to pain management, you have to agree to allow them to test your

blood for compliance to treatment.

Yes, the drug makes you sleep, only after making your feel like your are an

out of control drunk. I suspect that base on my age (58 and a half) that my body

doesn't metabolize very well. I also suspect that the back and abdominal pain

are from affects on kidneys and liver.

When swelling is a side effect, you may bet that there something toxic going

on. Lyrica is a narcotic. If I don't comply with treatment, the surgery to fix

my wrist and arm, will not happen; and, the good old worker's comp will say you

are as good as your going to get, because you don't comply with treatment. I

battled taking anything for as long as I could. I don't trust any drug approved

by the FDA.

Re: forced drugging / Lyrica (Pregabalin) -

Lyrica = (Pregabalin) which is this years

version of gabapentin (Neurontin) .... all made by my dear old

friends PFIZER

http://www.drugdevelopment-technology.com/projects/pregabalin/<http://www.drugde\

velopment-technology.com/projects/pregabalin/>

LYRICA (PREGABALIN) - NEW GABAPENTINOID WITH WIDE CLINICAL

APPLICATION

Developed by Pfizer, pregabalin, marketed under the brand name

Lyrica, is a 3-substituted analogue of gamma-amino butyric acid

(GABA) and a compound related to Pfizer's hugely successful

antiepileptic drug gabapentin (Neurontin).

In July 2004, Pfizer secured Europe-wide approval for Lyrica

(pregabalin) for use in the management of peripheral neuropathic

pain as well as an adjunctive therapy in the treatment of partial

epileptic seizures. Subsequently in December 2004 the company gained

FDA approval for use of Lyrica (pregabalin) in neuropathic pain

associated with diabetic peripheral neuropathy and postherpetic

neuralgia; making it the first FDA-approved treatment for both of

these neuropathic pain states. Lyrica (pregabalin) is also being

reviewed by the FDA as an adjunctive treatment for partial epileptic

seizures in adults.

A SUCCESSOR TO GABAPENTIN

First marketed in 1983, gabapentin (Neurontin) has been one of

Pfizer's top performing drugs. Lyrica (pregabalin) is seen as an

important successor now that gabapentin is facing the threat of

generic competition.

Both drugs share a similar mechanism of action: binding to calcium

channels and modulating calcium influx as well as influencing

GABergic neurotransmission. This mode of action translates into anti-

epileptic, analgesic and anxiolytic effects. Because it is more

potent than gabapentin, Lyrica (pregabalin) achieves efficacy at

lower doses. This increases its therapeutic index with respect to

gabapentin and should lead to fewer dose-related side effects.

Clinical studies with Lyrica (pregabalin) have been carried out on

over 10,000 patients worldwide.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN EPILEPSY

Gabapentin is approved worldwide for adjunctive treatment of

patients with partial epilepsy. Because it is not metabolised (and

so does not alter the pharmacokinetics of co-administrated drugs) it

is a good candidate for use in combination with other antiepileptic

medications. Clinical studies with oral Lyrica (pregabalin) suggest

it is at least as effective as gabapentin as adjunctive therapy in

patients refractory to one or more conventional antiepileptic drugs.

In large-scale, placebo-controlled studies of 12 weeks' duration,

add-on therapy with oral Lyrica (pregabalin) reduced seizure

frequency by up to 75%. In these studies doses of Lyrica

(pregabalin) ranged from 150mg to 600mg daily.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND

ANXIETY DISORDER

Neuropathic pain is chronic pain that arises from damage to sensory

nerves. It can include:

Pain arising from trapped or compressed nerves

Drug-induced nerve damage

Diabetic neuropathy

Post-herpetic pain

Phantom limb syndrome following limb amputation

Peripheral neuropathy

Fibromyalgia

Neuropathic pain generally does not respond to treatment with opioid

or non-steroidal anti-inflammatory drugs (NSAIDs). At high doses

gabapentin has proven effective against neuropathic pain induced by

diabetic neuropathy and postherpetic neuralgia. Data from clinical

studies show that Lyrica (pregabalin) shares this analgesic

effectiveness. Efficacy has been demonstrated in a number of

clinical studies, including those in patients with diabetic

neuropathy and fibromyalgia. Treatment of neuropathic pain is seen

as the drug's leading indication.

A double-blind, placebo-controlled monotherapy study in 529 patients

with fibromyalgia, for example, showed that eight weeks' treatment

with Lyrica (pregabalin) 150mg to 450mg per day produced

significantly greater reductions in pain compared with placebo as

well as improving sleep quality and fatigue. Pain, sleep

disturbances and fatigue are core symptoms of fibromyalgia, which

has proved an extremely difficult condition to treat.

Data from a series of phase II and III placebo-controlled clinical

studies in over 1,200 patients with generalised anxiety disorder

suggest that Lyrica (pregabalin) will be effective for this

disabling disorder. In comparison with venlafaxine, pregabalin

provided more rapid relief of psychic and somatic symptoms. In

comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin)

appeared equally effective in reducing somatic symptoms. Overall,

these findings show that Lyrica (pregabalin) combines the benefits

of both antidepressants and benzodiazepines. It appears at least as

rapid as benzodiazepines against somatic symptoms, while providing

more rapid control of psychic symptoms than antidepressants.

MARKETING COMMENTARY

Once generic manufacture of gabapentin is approved, sales of

Pfizer's Neurontin are likely to fall dramatically. Encouraging

physicians to switch patients from Neurontin to Lyrica (pregabalin),

if approved, will be an important strategy in minimising the impact

of generic competition. Lyrica (pregabalin) is as effective as

Neurontin, but at lower doses, which translates to fewer side

effects. Thus, it is well placed to capture Neurontin's market

share. Through the successful launch of follow-on products, Pfizer

has maintained leadership in other CNS areas, such as the market for

antidepressants.

Click here for printable version

SPECIFICATIONS

>

>

> In a message dated 10/14/2006 2:24:06 AM Pacific Standard Time,

> SSRI medications <mailto:SSRI medications >

writes:

>

> I am forced to take Lyrica, so that they can get RSD under

control. I now

> have more severe and acute back and abdominal pains, spasms

through out all my

> muscles, having a hard time concentrating, and forgetting little

things from

> minute to minute. Since it's a new drug, it will be years before

the damages

> are exposed

>

>

> How are you FORCED to take this? Are they using it in

suppository form?

> You can always not take it and tell them that you did? What is

Lyrica anyway?

> With the side effects you are experiencing, sounds like you need

to get off

> this poison.

>

>

>

[Guest guest]

When you go to pain management, you have to agree to allow them to test your

blood for compliance to treatment.

Yes, the drug makes you sleep, only after making your feel like your are an

out of control drunk. I suspect that base on my age (58 and a half) that my body

doesn't metabolize very well. I also suspect that the back and abdominal pain

are from affects on kidneys and liver.

When swelling is a side effect, you may bet that there something toxic going

on. Lyrica is a narcotic. If I don't comply with treatment, the surgery to fix

my wrist and arm, will not happen; and, the good old worker's comp will say you

are as good as your going to get, because you don't comply with treatment. I

battled taking anything for as long as I could. I don't trust any drug approved

by the FDA.

Re: forced drugging / Lyrica (Pregabalin) -

Lyrica = (Pregabalin) which is this years

version of gabapentin (Neurontin) .... all made by my dear old

friends PFIZER

http://www.drugdevelopment-technology.com/projects/pregabalin/<http://www.drugde\

velopment-technology.com/projects/pregabalin/>

LYRICA (PREGABALIN) - NEW GABAPENTINOID WITH WIDE CLINICAL

APPLICATION

Developed by Pfizer, pregabalin, marketed under the brand name

Lyrica, is a 3-substituted analogue of gamma-amino butyric acid

(GABA) and a compound related to Pfizer's hugely successful

antiepileptic drug gabapentin (Neurontin).

In July 2004, Pfizer secured Europe-wide approval for Lyrica

(pregabalin) for use in the management of peripheral neuropathic

pain as well as an adjunctive therapy in the treatment of partial

epileptic seizures. Subsequently in December 2004 the company gained

FDA approval for use of Lyrica (pregabalin) in neuropathic pain

associated with diabetic peripheral neuropathy and postherpetic

neuralgia; making it the first FDA-approved treatment for both of

these neuropathic pain states. Lyrica (pregabalin) is also being

reviewed by the FDA as an adjunctive treatment for partial epileptic

seizures in adults.

A SUCCESSOR TO GABAPENTIN

First marketed in 1983, gabapentin (Neurontin) has been one of

Pfizer's top performing drugs. Lyrica (pregabalin) is seen as an

important successor now that gabapentin is facing the threat of

generic competition.

Both drugs share a similar mechanism of action: binding to calcium

channels and modulating calcium influx as well as influencing

GABergic neurotransmission. This mode of action translates into anti-

epileptic, analgesic and anxiolytic effects. Because it is more

potent than gabapentin, Lyrica (pregabalin) achieves efficacy at

lower doses. This increases its therapeutic index with respect to

gabapentin and should lead to fewer dose-related side effects.

Clinical studies with Lyrica (pregabalin) have been carried out on

over 10,000 patients worldwide.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN EPILEPSY

Gabapentin is approved worldwide for adjunctive treatment of

patients with partial epilepsy. Because it is not metabolised (and

so does not alter the pharmacokinetics of co-administrated drugs) it

is a good candidate for use in combination with other antiepileptic

medications. Clinical studies with oral Lyrica (pregabalin) suggest

it is at least as effective as gabapentin as adjunctive therapy in

patients refractory to one or more conventional antiepileptic drugs.

In large-scale, placebo-controlled studies of 12 weeks' duration,

add-on therapy with oral Lyrica (pregabalin) reduced seizure

frequency by up to 75%. In these studies doses of Lyrica

(pregabalin) ranged from 150mg to 600mg daily.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND

ANXIETY DISORDER

Neuropathic pain is chronic pain that arises from damage to sensory

nerves. It can include:

Pain arising from trapped or compressed nerves

Drug-induced nerve damage

Diabetic neuropathy

Post-herpetic pain

Phantom limb syndrome following limb amputation

Peripheral neuropathy

Fibromyalgia

Neuropathic pain generally does not respond to treatment with opioid

or non-steroidal anti-inflammatory drugs (NSAIDs). At high doses

gabapentin has proven effective against neuropathic pain induced by

diabetic neuropathy and postherpetic neuralgia. Data from clinical

studies show that Lyrica (pregabalin) shares this analgesic

effectiveness. Efficacy has been demonstrated in a number of

clinical studies, including those in patients with diabetic

neuropathy and fibromyalgia. Treatment of neuropathic pain is seen

as the drug's leading indication.

A double-blind, placebo-controlled monotherapy study in 529 patients

with fibromyalgia, for example, showed that eight weeks' treatment

with Lyrica (pregabalin) 150mg to 450mg per day produced

significantly greater reductions in pain compared with placebo as

well as improving sleep quality and fatigue. Pain, sleep

disturbances and fatigue are core symptoms of fibromyalgia, which

has proved an extremely difficult condition to treat.

Data from a series of phase II and III placebo-controlled clinical

studies in over 1,200 patients with generalised anxiety disorder

suggest that Lyrica (pregabalin) will be effective for this

disabling disorder. In comparison with venlafaxine, pregabalin

provided more rapid relief of psychic and somatic symptoms. In

comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin)

appeared equally effective in reducing somatic symptoms. Overall,

these findings show that Lyrica (pregabalin) combines the benefits

of both antidepressants and benzodiazepines. It appears at least as

rapid as benzodiazepines against somatic symptoms, while providing

more rapid control of psychic symptoms than antidepressants.

MARKETING COMMENTARY

Once generic manufacture of gabapentin is approved, sales of

Pfizer's Neurontin are likely to fall dramatically. Encouraging

physicians to switch patients from Neurontin to Lyrica (pregabalin),

if approved, will be an important strategy in minimising the impact

of generic competition. Lyrica (pregabalin) is as effective as

Neurontin, but at lower doses, which translates to fewer side

effects. Thus, it is well placed to capture Neurontin's market

share. Through the successful launch of follow-on products, Pfizer

has maintained leadership in other CNS areas, such as the market for

antidepressants.

Click here for printable version

SPECIFICATIONS

>

>

> In a message dated 10/14/2006 2:24:06 AM Pacific Standard Time,

> SSRI medications <mailto:SSRI medications >

writes:

>

> I am forced to take Lyrica, so that they can get RSD under

control. I now

> have more severe and acute back and abdominal pains, spasms

through out all my

> muscles, having a hard time concentrating, and forgetting little

things from

> minute to minute. Since it's a new drug, it will be years before

the damages

> are exposed

>

>

> How are you FORCED to take this? Are they using it in

suppository form?

> You can always not take it and tell them that you did? What is

Lyrica anyway?

> With the side effects you are experiencing, sounds like you need

to get off

> this poison.

>

>

>

[Guest guest]

When you go to pain management, you have to agree to allow them to test your

blood for compliance to treatment.

Yes, the drug makes you sleep, only after making your feel like your are an

out of control drunk. I suspect that base on my age (58 and a half) that my body

doesn't metabolize very well. I also suspect that the back and abdominal pain

are from affects on kidneys and liver.

When swelling is a side effect, you may bet that there something toxic going

on. Lyrica is a narcotic. If I don't comply with treatment, the surgery to fix

my wrist and arm, will not happen; and, the good old worker's comp will say you

are as good as your going to get, because you don't comply with treatment. I

battled taking anything for as long as I could. I don't trust any drug approved

by the FDA.

Re: forced drugging / Lyrica (Pregabalin) -

Lyrica = (Pregabalin) which is this years

version of gabapentin (Neurontin) .... all made by my dear old

friends PFIZER

http://www.drugdevelopment-technology.com/projects/pregabalin/<http://www.drugde\

velopment-technology.com/projects/pregabalin/>

LYRICA (PREGABALIN) - NEW GABAPENTINOID WITH WIDE CLINICAL

APPLICATION

Developed by Pfizer, pregabalin, marketed under the brand name

Lyrica, is a 3-substituted analogue of gamma-amino butyric acid

(GABA) and a compound related to Pfizer's hugely successful

antiepileptic drug gabapentin (Neurontin).

In July 2004, Pfizer secured Europe-wide approval for Lyrica

(pregabalin) for use in the management of peripheral neuropathic

pain as well as an adjunctive therapy in the treatment of partial

epileptic seizures. Subsequently in December 2004 the company gained

FDA approval for use of Lyrica (pregabalin) in neuropathic pain

associated with diabetic peripheral neuropathy and postherpetic

neuralgia; making it the first FDA-approved treatment for both of

these neuropathic pain states. Lyrica (pregabalin) is also being

reviewed by the FDA as an adjunctive treatment for partial epileptic

seizures in adults.

A SUCCESSOR TO GABAPENTIN

First marketed in 1983, gabapentin (Neurontin) has been one of

Pfizer's top performing drugs. Lyrica (pregabalin) is seen as an

important successor now that gabapentin is facing the threat of

generic competition.

Both drugs share a similar mechanism of action: binding to calcium

channels and modulating calcium influx as well as influencing

GABergic neurotransmission. This mode of action translates into anti-

epileptic, analgesic and anxiolytic effects. Because it is more

potent than gabapentin, Lyrica (pregabalin) achieves efficacy at

lower doses. This increases its therapeutic index with respect to

gabapentin and should lead to fewer dose-related side effects.

Clinical studies with Lyrica (pregabalin) have been carried out on

over 10,000 patients worldwide.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN EPILEPSY

Gabapentin is approved worldwide for adjunctive treatment of

patients with partial epilepsy. Because it is not metabolised (and

so does not alter the pharmacokinetics of co-administrated drugs) it

is a good candidate for use in combination with other antiepileptic

medications. Clinical studies with oral Lyrica (pregabalin) suggest

it is at least as effective as gabapentin as adjunctive therapy in

patients refractory to one or more conventional antiepileptic drugs.

In large-scale, placebo-controlled studies of 12 weeks' duration,

add-on therapy with oral Lyrica (pregabalin) reduced seizure

frequency by up to 75%. In these studies doses of Lyrica

(pregabalin) ranged from 150mg to 600mg daily.

CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND

ANXIETY DISORDER

Neuropathic pain is chronic pain that arises from damage to sensory

nerves. It can include:

Pain arising from trapped or compressed nerves

Drug-induced nerve damage

Diabetic neuropathy

Post-herpetic pain

Phantom limb syndrome following limb amputation

Peripheral neuropathy

Fibromyalgia

Neuropathic pain generally does not respond to treatment with opioid

or non-steroidal anti-inflammatory drugs (NSAIDs). At high doses

gabapentin has proven effective against neuropathic pain induced by

diabetic neuropathy and postherpetic neuralgia. Data from clinical

studies show that Lyrica (pregabalin) shares this analgesic

effectiveness. Efficacy has been demonstrated in a number of

clinical studies, including those in patients with diabetic

neuropathy and fibromyalgia. Treatment of neuropathic pain is seen

as the drug's leading indication.

A double-blind, placebo-controlled monotherapy study in 529 patients

with fibromyalgia, for example, showed that eight weeks' treatment

with Lyrica (pregabalin) 150mg to 450mg per day produced

significantly greater reductions in pain compared with placebo as

well as improving sleep quality and fatigue. Pain, sleep

disturbances and fatigue are core symptoms of fibromyalgia, which

has proved an extremely difficult condition to treat.

Data from a series of phase II and III placebo-controlled clinical

studies in over 1,200 patients with generalised anxiety disorder

suggest that Lyrica (pregabalin) will be effective for this

disabling disorder. In comparison with venlafaxine, pregabalin

provided more rapid relief of psychic and somatic symptoms. In

comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin)

appeared equally effective in reducing somatic symptoms. Overall,

these findings show that Lyrica (pregabalin) combines the benefits

of both antidepressants and benzodiazepines. It appears at least as

rapid as benzodiazepines against somatic symptoms, while providing

more rapid control of psychic symptoms than antidepressants.

MARKETING COMMENTARY

Once generic manufacture of gabapentin is approved, sales of

Pfizer's Neurontin are likely to fall dramatically. Encouraging

physicians to switch patients from Neurontin to Lyrica (pregabalin),

if approved, will be an important strategy in minimising the impact

of generic competition. Lyrica (pregabalin) is as effective as

Neurontin, but at lower doses, which translates to fewer side

effects. Thus, it is well placed to capture Neurontin's market

share. Through the successful launch of follow-on products, Pfizer

has maintained leadership in other CNS areas, such as the market for

antidepressants.

Click here for printable version

SPECIFICATIONS

>

>

> In a message dated 10/14/2006 2:24:06 AM Pacific Standard Time,

> SSRI medications <mailto:SSRI medications >

writes:

>

> I am forced to take Lyrica, so that they can get RSD under

control. I now

> have more severe and acute back and abdominal pains, spasms

through out all my

> muscles, having a hard time concentrating, and forgetting little

things from

> minute to minute. Since it's a new drug, it will be years before

the damages

> are exposed

>

>

> How are you FORCED to take this? Are they using it in

suppository form?

> You can always not take it and tell them that you did? What is

Lyrica anyway?

> With the side effects you are experiencing, sounds like you need

to get off

> this poison.

>

>

>